| MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) (NCT03412292) | Maxinovel Pty., Ltd. | 2018-08-01 |
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study (NCT03260101) | Cellect Biotechnology | 2018-06-10 |
| A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia (NCT03600909) | Memorial Sloan Kettering Cancer Center | 2018-05-15 |
| Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT (NCT02989844) | Masonic Cancer Center, University of Minnesota | 2017-04-12 |
| Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS (NCT02730299) | Gamida Cell ltd | 2016-12-16 |
| Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer (NCT02240537) | Benovus Bio, Inc. | 2015-01-01 |
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (NCT02226861) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-08-26 |
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs (NCT02200380) | Celldex Therapeutics | 2014-07-01 |
| Red Cell Transfusion Goals in Patients With Acute Leukemias (NCT02086773) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-04-01 |
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (NCT02143830) | Children's Hospital Medical Center, Cincinnati | 2014-04-01 |
| Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse (NCT01995578) | Memorial Sloan Kettering Cancer Center | 2013-12-01 |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT (NCT01885897) | Masonic Cancer Center, University of Minnesota | 2013-11-11 |
| Omacetaxine for Consolidation and Maintenance (NCT01873495) | Emory University | 2013-05-01 |
| Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS (NCT02124174) | Patrick Stiff | 2012-01-01 |
| Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649) (NCT01451437) | Merck Sharp & Dohme LLC | 2011-11-18 |
| Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML) (NCT01265199) | Ascenta Therapeutics | 2011-02-01 |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies (NCT01221857) | Gamida Cell ltd | 2010-11-01 |
| Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) (NCT01113502) | Abramson Cancer Center at Penn Medicine | 2010-06-01 |
| A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects (NCT00943553) | Eisai Inc. | 2010-06-01 |
| Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells (NCT01050764) | Everett Meyer | 2009-06-01 |
| Unrelated Umbilical Cord Blood (UBC)Transplantation (NCT01768845) | West Virginia University | 2009-02-03 |
| Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002) (NCT00779480) | Kyowa Kirin Co., Ltd. | 2009-01-01 |
| Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia (NCT00528983) | Celgene | 2007-09-11 |
| A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation (NCT00672152) | Michael Morse, MD | 2007-06-01 |
| Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant (NCT00088543) | Genzyme, a Sanofi Company | 2004-03-01 |
| Expanded Access for CC-486 (NCT03723135) | Celgene | |